IL300547A - Microsphere formulations comprising ketamine and methods for their production and use - Google Patents

Microsphere formulations comprising ketamine and methods for their production and use

Info

Publication number
IL300547A
IL300547A IL300547A IL30054723A IL300547A IL 300547 A IL300547 A IL 300547A IL 300547 A IL300547 A IL 300547A IL 30054723 A IL30054723 A IL 30054723A IL 300547 A IL300547 A IL 300547A
Authority
IL
Israel
Prior art keywords
polymer
microsphere
ketamine
microspheres
polymer microspheres
Prior art date
Application number
IL300547A
Other languages
English (en)
Hebrew (he)
Inventor
GALASKA Rachel
KAHT Kelsey
Richey Tracy
Original Assignee
Oakwood Laboratories LLC
GALASKA Rachel
KAHT Kelsey
Richey Tracy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC, GALASKA Rachel, KAHT Kelsey, Richey Tracy filed Critical Oakwood Laboratories LLC
Publication of IL300547A publication Critical patent/IL300547A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
IL300547A 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for their production and use IL300547A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067068P 2020-08-18 2020-08-18
US202163149911P 2021-02-16 2021-02-16
PCT/US2021/046220 WO2022040130A1 (en) 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for making and using the same

Publications (1)

Publication Number Publication Date
IL300547A true IL300547A (en) 2023-04-01

Family

ID=80270269

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300547A IL300547A (en) 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for their production and use

Country Status (10)

Country Link
US (1) US12233165B2 (cg-RX-API-DMAC7.html)
EP (1) EP4199917B1 (cg-RX-API-DMAC7.html)
JP (1) JP7814375B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230052915A (cg-RX-API-DMAC7.html)
CN (1) CN115942935B (cg-RX-API-DMAC7.html)
AU (1) AU2021329820A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191160A1 (cg-RX-API-DMAC7.html)
IL (1) IL300547A (cg-RX-API-DMAC7.html)
TW (1) TWI906350B (cg-RX-API-DMAC7.html)
WO (1) WO2022040130A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
EP4611729A1 (en) * 2022-10-31 2025-09-10 Oakwood Laboratories, LLC Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720859B2 (ja) * 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU6510400A (en) * 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
US6479007B1 (en) 1999-09-16 2002-11-12 University Technology Corporation Apparatus and method for controlling pore size in polymeric membranes and thin films
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
WO2002089767A1 (en) * 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050260272A1 (en) 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
EP1996243B1 (en) * 2006-01-11 2014-04-23 HyperBranch Medical Technology, Inc. Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
US20070292521A1 (en) * 2006-06-20 2007-12-20 Schwitzer Co., Ltd Oral Encapsulated Preparation for Aquatic Animals
US20110027331A1 (en) 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation
SG11201404038PA (en) * 2012-02-06 2014-08-28 Univ Nanyang Tech Methods of manufacturing core-shell microparticles, and microparticles formed thereof
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP3368553B1 (en) 2015-10-27 2023-08-02 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
SG11202001206YA (en) 2017-09-14 2020-03-30 Agency Science Tech & Res Emulsions, methods and uses thereof
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3968979B1 (en) 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
KR102474965B1 (ko) 2019-07-01 2022-12-07 오크우드 레버러토리즈, 엘엘씨 마이크로스피어 및 에멀션 제조하기 위한 시스템 및 방법
WO2021108801A2 (en) 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists
IL294089B1 (en) 2019-12-20 2026-07-01 Alar Pharmaceuticals Inc Injectable, long-acting formulations of ketamine pamoate salts
US20210361578A1 (en) 2020-04-03 2021-11-25 University Of Iowa Research Foundation Mek1/2 inhibitor-loaded microparticle formulation

Also Published As

Publication number Publication date
JP2023538901A (ja) 2023-09-12
EP4199917C0 (en) 2026-01-07
EP4199917A4 (en) 2024-10-30
KR20230052915A (ko) 2023-04-20
US12233165B2 (en) 2025-02-25
US20220054420A1 (en) 2022-02-24
EP4199917A1 (en) 2023-06-28
CN115942935B (zh) 2025-09-05
TWI906350B (zh) 2025-12-01
WO2022040130A1 (en) 2022-02-24
CN115942935A (zh) 2023-04-07
CA3191160A1 (en) 2022-02-24
JP7814375B2 (ja) 2026-02-16
AU2021329820A1 (en) 2023-03-09
EP4199917B1 (en) 2026-01-07
TW202227044A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
IL269205A (en) Solid amorphous dispersion for use in the treatment of a patient with lung cancer who responds positively to erbb2
NZ533435A (en) Injectable depot compositions and uses thereof
NZ575744A (en) Pharmaceutical compositions of clonazepam and methods of use thereof
JP2016513721A (ja) 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法
CN102949375B (zh) 一种盐酸小檗碱固体脂质纳米制剂及其制备方法
NZ551748A (en) Irinotecan formulation
KR20080028289A (ko) 수 난용성 캄토테신 유도체의 미세 나노입자 및 그의제조방법
IL293835A (en) Formulations for cryprazine release
EP3946272B1 (en) Method for preparing biocompatible polymer-based apixaban-loaded microspheres
CN113891705B (zh) 用于制备负载阿哌沙班的微球的分散相的组合物和由其制备的基于生物相容性聚合物的负载阿哌沙班的微球
CN110769813A (zh) 包含具有双核壳结构的难溶性喜树碱化合物的粒子、药剂学组合物及其制备方法
EP4199917B1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
Ingabire et al. Nor-LAAM loaded PLGA microparticles for treating opioid use disorder
IL273988B2 (en) Cannabidiol and chitosan compositions and methods of using the same
WO2022183196A1 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
IL256504A (en) Solid pharmaceutical preparations for the treatment of hcv
IL322310A (en) Methods for treating multiple sclerosis complex
JP5613396B2 (ja) 腸管吸収性を改善する医薬組成物
CN102293748A (zh) 一种口服聚乙二醇化胰岛素pH敏感纳米粒及其制备方法
Ren et al. Novel Supramolecular Nanoparticles Modified with Phosphatidylcholine Improve the Bioavailability of Fisetin and Alleviate Alcoholism through Antioxidant and Antiinflammatory Effects
US20240216280A1 (en) Microsphere formulations comprising nalmefene andmethods for making and using the same
IL287590B1 (en) Mini softgel naproxen composition
JP2024536879A5 (cg-RX-API-DMAC7.html)
US20230225993A1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20240342115A1 (en) Microsphere formulations comprising ketamine and methods formaking and using the same